PA
ANIK icon

Parallel Advisors’s Anika Therapeutics ANIK Stock Holding History

Parallel Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-39
Closed -$963 – 3522
2024
Q3 		$963 Hold
39
– – ﹤0.01% 3047
2024
Q2 		$988 Hold
39
– – ﹤0.01% 2960
2024
Q1 		$991 Buy
+39
New +$944 ﹤0.01% 2933
2023
Q4 		– Sell
-14
Closed -$261 – 3320
2023
Q3 		$261 Sell
14
-99
-88% -$2.05K ﹤0.01% 3205
2023
Q2 		$2.94K Buy
113
+29
+35% +$776 ﹤0.01% 2624
2023
Q1 		$2.41K Hold
84
– – ﹤0.01% 2698
2022
Q4 		$2.49K Hold
84
– – ﹤0.01% 2603
2022
Q3 		$2K Buy
84
+78
+1,300% +$1.79K ﹤0.01% 2579
2022
Q2 		$0 Buy
+6
New +$134 ﹤0.01% 2968
2018
Q4 		– Sell
-211
Closed -$7.62K – 2107
2018
Q3 		$9K Hold
211
– – ﹤0.01% 1466
2018
Q2 		$6K Hold
211
– – ﹤0.01% 1511
2018
Q1 		$10K Hold
211
– – ﹤0.01% 1248
2017
Q4 		$11K Hold
211
– – ﹤0.01% 1257
2017
Q3 		$11K Hold
211
– – ﹤0.01% 1236
2017
Q2 		$11K Buy
+211
New +$9.72K ﹤0.01% 1262

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $333M AUM 102.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Parallel Advisors's ANIK Position: Q4 2024 in Review

Parallel Advisors sold out of Anika Therapeutics (ANIK) in Q4 2024, closing a stake of 39 shares — an estimated $963 sold.

Parallel Advisors first reported a position in ANIK in Q2 2017 and held it in 15 quarters. The position peaked at $11K in Q4 2017. 109 funds tracked by Wall St. Rank hold ANIK as of Q4 2024.

  • Parallel Advisors reported no remaining Anika Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Parallel Advisors sold 39 Anika Therapeutics shares in Q4 2024, an estimated $963.
  • Parallel Advisors first reported a position in Anika Therapeutics in Q2 2017 and held it in 15 quarters.
  • Parallel Advisors's Anika Therapeutics position peaked at $11K in Q4 2017.
  • 109 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2024.

Based on Parallel Advisors's 13F filing for Q4 2024, filed 10 Feb 2025.